What is the typical KPV dose?
Preclinical KPV research protocols typically use dose ranges in the 200-500 mcg per dose tier, with administration route and frequency depending on the specific experimental context. The intestinal-inflammation framework focuses on PepT1-mediated uptake at the intestinal mucosa rather than systemic circulating concentrations.
What the research literature says
The KPV dose framework is informed by the published research literature on PepT1-mediated intestinal-epithelial uptake. The Dalmasso PepT1-uptake characterisation (PMID 18061177) and the Kannengiesser anti-inflammatory work in murine IBD models (PMID 18092346) established the dose tiers and administration approaches that anchor subsequent protocols.
The Viennois colitis-associated cancer work (PMID 27458604) and the Xiao oral-targeted-delivery work using hyaluronic-acid-functionalised nanoparticles (PMID 28143741) extended the dose-and-delivery framework into more nuanced experimental contexts. Oral administration is the most common route for the intestinal-inflammation framework specifically because the PepT1-uptake mechanism operates at the intestinal mucosa; subcutaneous administration is less common for this compound.
The compound’s pharmacology is concentrated at the intestinal mucosa rather than systemically — the plasma half-life is short and the functional response time scale derives from the cellular-uptake-and-NF-κB-modulation pharmacology rather than from systemic circulating concentrations.
Why this matters in research context
KPV’s dose framework is more context-specific than most catalog compounds because the PepT1-uptake pharmacology operates differently at the intestinal mucosa than would systemic distribution. Researchers should anchor protocol design to the specific experimental context (oral vs other administration route, GI-inflammation vs other applications) rather than treating the compound as a generic systemic anti-inflammatory tool.
Related compounds
- KPV 10mg — the compound covered by this answer
- KLOW Blend — four-compound formulation including KPV
Related research questions
References
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134(1):166-178. [PMID 18061177]
- Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008;14(3):324-331. [PMID 18092346]
- Viennois E et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol 2016;2(3):340-357. [PMID 27458604]
- Xiao B et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther 2017;25(7):1628-1640. [PMID 28143741]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. KPV is sold strictly as a research-grade reagent for laboratory and bench research applications.